Home › Funds › Merck & Co., Inc. › AKTS

Merck & Co., Inc. position in AKTS

AKTIS ONCOLOGY INC · Health Care

Merck & Co., Inc. reported holding 952,844 shares of AKTS (AKTIS ONCOLOGY INC) in its Q3 2026 13F filing — a position valued at US$18.6M, representing 2.26% of its reported portfolio and ranking #4 among its reported holdings. Merck & Co., Inc. has disclosed AKTS holdings in 3 of the last 3 reported quarters, going back to Q1 2026.

Latest position (Q3 2026)952.84K sh
Reported value held$18.55M
Portfolio Weight2.26%
First reportedQ1 2026
Last changeHold
Updated2026-11-14

Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR

How Merck & Co., Inc.'s AKTS position evolved

Merck & Co., Inc. first disclosed a stake in AKTS in Q1 2026 at 952,844 shares (US$17.0M). The position peaked in Q2 2026 at 952,844 shares, worth US$30.7M. Across 3 filings, Merck & Co., Inc. held the position steady without any share-count change. The most recent filing (Q3 2026) shows 952,844 shares valued at US$18.6M.

Quarter by quarter

QuarterSharesValueChange
Q1 2026 952.84K $17.05M New
Q2 2026 952.84K $30.71M Hold
Q3 2026 952.84K $18.55M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About AKTS and 13F data

AKTS (AKTIS ONCOLOGY INC) is a Health Care company. 126 other funds we track also report a position in AKTS — the largest reported positions include MPM BioImpact LLC (US$155.9M), EcoR1 Capital, LLC (US$155.5M), Blue Owl Capital Holdings LP (US$65.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding AKTS

All AKTS fund holders →

FAQ

How long has Merck & Co., Inc. held AKTS?

Merck & Co., Inc. has disclosed AKTS holdings in 3 of the last 3 reported quarters, going back to Q1 2026.

What is Merck & Co., Inc.'s current position in AKTS?

As of Q3 2026, Merck & Co., Inc. holds 952.84K shares of AKTS (AKTIS ONCOLOGY INC), valued at $18.55M, representing 2.26% of its reported portfolio and ranking #4.

Has Merck & Co., Inc. been buying or selling AKTS?

In the latest 13F filing (Q3 2026), Merck & Co., Inc. held unchanged its position in AKTS. The position peaked in Q2 2026 at 952.84K shares.

Which other funds hold AKTS?

Other major institutional holders of AKTS include MPM BioImpact LLC, EcoR1 Capital, LLC, Blue Owl Capital Holdings LP, among 126 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.